PHILADELPHIA, January 10, 2012 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced today that it has acquired the rights to develop and market Resolor(R) (prucalopride) in the United States (US) in an agreement with Janssen Pharmaceutica N.V. Terms of the ... read more

PHILADELPHIA, Dec. 2, 2011 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that it has reached an agreement with the Center for Drug Evaluation and Research (CDER) at the U.S. Food and Drug Administration (FDA) to conduct additional clinical trials ... read more

PHILADELPHIA, Dec. 1, 2011 /PRNewswire/ -- Shire plc, the global specialty biopharmaceutical company, responds to questions about reports of a supply shortage of ADDERALL® (mixed salts of a single-entity amphetamine product) Tablets, CII. ADDERALL® is an immediate release formulation and is sometimes referred to as "ADDERALL IR." While ... read more

NYON, Switzerland and PHILADELPHIA, November 18, 2011 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that it has entered into an agreement with Shionogi & Co. Ltd. of Japan to co-develop and co-commercialize certain of Shire's Attention Deficit Hyperactivity Disorder ... read more

PHILADELPHIA, Sept. 22, 2011 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces an update on the approval status and availability of ProAmatine® (midodrine HCl), a medicine approved for the treatment of symptomatic orthostatic hypotension (SOH). Shire has engaged in consistent dialogue with the ... read more

DUBLIN, Ireland and LEXINGTON, Massachusetts, August 25, 2011 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for FIRAZYR(R) (icatibant injection) for treatment of acute attacks of hereditary angioedema ... read more